InterCure Reports Strong FY2023: Performance Paves the Way for Global Expansion

Steady Financial Growth

InterCure Ltd. (NASDAQ:INCR) achieved significant financial success in FY2023, reporting a total revenue of approximately USD 95.2 million. The company showcased an adjusted EBITDA of around USD 16.3 million, representing 17% of its total revenues. This performance marks an improvement over the preliminary results, which estimated an adjusted EBITDA of around USD 13.6 million.

Navigating Operational Challenges

InterCure maintained its profitability streak, ending the third and fourth quarters of 2023 with positive EBITDA and operational profits. The company effectively …

Full story available on Benzinga.com